Pharma Deadline Extended: Govt Grants Relief to Small & Medium Firms

The Ministry of Health & Family Welfare has given three months from February 11, 2025, to the small and medium pharmaceutical firms to submit their plan for upgradation to the central license approving authority in order to be eligible to qualify for Schedule M deadline extension, the ministry said in a release.

The ministry further said it has conditionally extended the due date for implementation of revised Schedule M, the good manufacturing practices provision, in respect of small and medium manufacturers having turnover of Rs 250 crore or less, up to December 31, 2025.

On December 28, 2023, the Centre notified revised ‘Schedule M’ requirements wherein “good manufacturing practices” was upgraded to “good manufacturing practices and requirements of plan and equipment for pharmaceutical products”.

Under this, manufacturers were divided into two groups with the first category of large manufacturers having turnover more than Rs 250 crore. A timeline of six months was given to such manufacturers for compliance and the revised Schedule M requirements have been implemented for these manufacturers from June 28, 2024.

For small and medium manufacturers with turnover less than or equal to Rs 250 crore, a timeline of 12 months was given for compliance.

“Small and medium manufacturers had represented for extension of timeline to enable improvement in infrastructure, training of personnel and arranging financial resources,” the ministry said.

It added, “The same has been considered and the small and medium manufacturers have been given a time of three months from February 11, 2025, to submit their plan for upgradation in Form A to the Central License Approving Authority. For such manufacturers who submit these details, the timeline of implementation would be extended till December 31, 2025.”

The revised Schedule M requirements are a positive step towards ensuring the quality and safety of pharmaceutical products being manufactured in India, the ministry said.

The new regulations would enable the pharma companies to not only strengthen their domestic position but also become more competitive globally, it added.

Source: PTI

Related Posts

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital, Kengeri, Bengaluru, part of the Fortis Healthcare Network, marked World Organ Donation Day with its annual commemorative event, ‘A Legacy That Lives On.’ The event brought together…

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Punjab: The Narcotics Control Bureau (NCB) has uncovered an alleged pharmaceutical-drug diversion network operating through rural areas of Punjab. Investigators are tracing the movement of fentanyl and other drugs regulated…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses

Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses